You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 46 No. 4, April 1989 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (96)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Outpatient Treatment of 'Crack' Cocaine Smoking With Flupenthixol Decanoate

A Preliminary Report

Frank H. Gawin, MD; David Allen, MD; Brian Humblestone, MB

Arch Gen Psychiatry. 1989;46(4):322-325.


Abstract



• "Crack" cocaine abuse often produces severe cocaine dependence that is refractory to available pharmacological and outpatient psychotherapeutic treatments. We conducted two preliminary investigations evaluating the efficacy of flupenthixol decanoate, a depot xanthene requiring infrequent intramuscular administration, in the treatment of cocaine withdrawal. Ten outpatient crack cocaine smokers with poor prognoses were administered flupenthixol decanoate in an open-label, open-ended trial. Flupenthixol decanoate was well tolerated and appeared to decrease cocaine craving and use markedly and rapidly, producing a 260% increase in the average time retained in treatment among these subjects. These promising but preliminary data, combined with the magnitude of problems presented by crack, warrant rapid, expanded double-blind assessment of flupenthixol decanoate in cocaine-abuse treatment.



Author Affiliations



From the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn (Dr Gawin); and The Princess Margaret Hospital (Dr Allen) and The Sandilands Hospital (Dr Humblestone), Nassau, Bahamas.


Footnotes



Accepted for publication February 22, 1989.

Reprint requests to Substance Abuse Research Unit, Department of Psychiatry, Yale University School of Medicine, 27 Sylvan Ave, New Haven, CT 06519 (Dr Gawin).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study
Wiesbeck et al.
Alcohol Alcohol 2001;36:329-334.
ABSTRACT | FULL TEXT  

New Pharmacotherapies for Cocaine Dependence... Revisited
Meyer
Arch Gen Psychiatry 1992;49:900-904.
ABSTRACT  

Cocaine addiction: psychology and neurophysiology
Gawin
Science 1991;251:1580-1586.
ABSTRACT  

The drug dilemma: manipulating the demand
Jarvik
Science 1990;250:387-392.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.